Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim...

Related Keywords

Vancouver ,British Columbia ,Canada ,South Korea ,Ireland ,United States ,American ,Taiho Lonsurf ,E Russell Mcallister ,Bayer Stivarga ,American Society Of Clinical Oncology ,American Association For Cancer Research ,Bold Therapeutics Inc ,American Association ,Cancer Research ,Circulating Cytokine Changes When Administered ,Advanced Gastrointestinal Cancer Patients ,Dose Escalation Study ,Pre Treated Advanced Colorectal Cancer ,Interim Efficacy ,Tolerability Analysis ,American Society ,Clinical Oncology ,Bold Therapeutics ,Bold Therapeutic ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,